Business
Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility, tolerability and high T-cell
About this update from Immatics N.v.
[{"type":"text","content":"Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility, tolerability and high T-cell persistence.Clinical courses observed in patients indicate COL6A3 exon 6 as a potentially valuable tumor target for continued evaluation.The data support further exploration of a multi-target ACT approach using potent T cell receptors (TCRs) Tuebingen, Germany and Houston, Texas, November 10, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today that the Company will present Phase I results from their ACTolog® program IMA101 at the 35th Annual SITC Meeting, held virtually from November 9-14, 2020. ACTolog® is a pilot study for a personalized multi-TCR-T approach that aims to address current challenges for effective cancer immunotherapy, such as tumor heterogeneity and tumor immune escape. The data to be presented demonstrate the feasibility of the approach while also showing the therapy is well tolerated. In addition, case studies within the treated patient population support further exploration of a personalized ACT approach using potent high-affinity TCRs. \n The data will be presented at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting on November 11. Clinical Data Highlights 14 patients with relapsed/refractory solid tumors received adoptive cell therapy IMA101 directed against defined pHLA targets specific to each patient ACTolog® demonstrates feasibility of a multi-target multi-T cell product approach The target positivity rate of 90% demonstrated that such a multi-target approach leads to minimal patient attrition during screening due to lack of target expression.Each product combination in the ACTolog® multi-target approach was guided by confirmed target expression in patient-derived biopsies. ACTolog® was well-tolerated in heavily pretreated patients Common adverse events included expected cytopenias, mostly associated with the lymphodepleting regime and in many cases accompanied by Grade 1-2 cytokine release syndrome. ACTolog® shows remarkable T cell persistence and tumor infiltration ACTolog® treatment resulted in high target-specific T cell levels and persistence with total frequencies up to ~80% of all ...